Exist­ing investor con­fi­dence is reflected in Smart­Dye­Liv­ery GmbH’s lat­est financ­ing round

After a suc­cess­ful 2023 and reg­u­la­tory approval to con­duct the Phase I clin­i­cal trial for its first plat­form-based prod­uct, Smart­Dye­Liv­ery has once again reaf­firmed the con­fi­dence of its investors. The investors con­tinue to be fully con­fi­dent in the company’s devel­op­ment and are invest­ing a multi-mil­lion Euro amount for the future devel­op­ment of SmartDyeLivery’s uni­ver­sal drug deliv­ery plat­form. In addi­tion to bm‑t beteili­gungs­man­age­ment thürin­gen gmbh (bm|t) as lead investor, a busi­ness angel and a fam­ily office also par­tic­i­pated in the round col­lec­tive, thus sup­port­ing the growth of the inno­v­a­tive com­pany from Jena.

“We are extremely grate­ful for this pos­i­tive start of the new year and the con­tin­ued sup­port of our investors. 2024 will be an excit­ing year for us, which will be char­ac­terised pri­mar­ily by the start of our clin­i­cal trial, and we are look­ing for­ward to the fur­ther devel­op­ments”, says Dr. Marc Lehmann, Man­ag­ing Direc­tor of Smart­Dye­Liv­ery. With the newly raised cap­i­tal and the immi­nent first appli­ca­tion in humans immi­nent, the com­pany has a promis­ing busi­ness year ahead.

About SmartDyeLivery:

Smart­Dye­Liv­ery GmbH from Jena is devel­op­ing a uni­ver­sal plat­form tech­nol­ogy based on func­tion­alised nanopar­ti­cles that can be used to trans­port active ingre­di­ents or other car­goes to the desired tar­get site. The aim is to pro­vide new ther­a­peu­tic options for dis­eases that were pre­vi­ously untreat­able or dif­fi­cult to treat. The inno­v­a­tive, patent-pro­tected tech­nol­ogy can also be used for diag­nos­tic or ther­a­nos­tic applications.
Fur­ther infor­ma­tion can be found at www.smartdyelivery.com

About bm|t:

bm|t, based in Erfurt, is a sub­sidiary of Thüringer Auf­baubank and the lead­ing address for invest­ments in Thuringia. bm|t cur­rently man­ages twelve funds with a total vol­ume of around EUR 445 mil­lion, which are to be invested in inno­v­a­tive com­pa­nies in almost all sec­tors and in all phases of cor­po­rate devel­op­ment — both in the start-up and growth phases or in com­pany suc­ces­sion situations.
Fur­ther infor­ma­tion can be found at www.bm‑t.com